Session » Abstracts: Immunological Complications of Therapy (0437–0440)
-
Abstract Number: 0437
Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
-
Abstract Number: 0438
Rheumatological Immune-Related Adverse Events of Immune Checkpoint Inhibitors Based on the FDA Adverse Event Reporting System
-
Abstract Number: 0439
Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer
-
Abstract Number: 0440
Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events